We are live on ! Find out more
NVS icon

Novartis

937 hedge funds and large institutions have $22.2B invested in Novartis in 2017 Q3 according to their latest regulatory filings, with 70 funds opening new positions, 348 increasing their positions, 336 reducing their positions, and 44 closing their positions.

New
Increased
Maintained
Reduced
Closed

86% more call options, than puts

Call options by funds: $41.3M | Put options by funds: $22.2M

59% more first-time investments, than exits

New positions opened: 70 | Existing positions closed: 44

2% more funds holding

Funds holding: 920937 (+17)

4% more repeat investments, than reductions

Existing positions increased: 348 | Existing positions reduced: 336

2% more capital invested

Capital invested by funds: $21.7B → $22.2B (+$474M)

0.06% less ownership

Funds ownership: 11.09%11.03% (-0.06%)

5% less funds holding in top 10

Funds holding in top 10: 4038 (-2)

Holders
937
Holders Change
+17
Holders Change %
+1.85%
% of All Funds
23.36%
Holding in Top 10
38
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-5%
% of All Funds
0.95%
New
70
Increased
348
Reduced
336
Closed
44
Calls
$41.3M
Puts
$22.2M
Net Calls
+$19.2M
Net Calls Change
-$5M
Name Holding Trade Value Shares
Change
Change in
Stake
Jane Street
126
Jane Street
New York
$15.4M +$5.03M +66,637 +50%
EWA
127
Exencial Wealth Advisors
Oklahoma
$15.1M +$102K +1,355 +0.7%
Fiera Capital (Canada)
128
Fiera Capital (Canada)
Quebec, Canada
$15.1M -$10.4M -137,724 -41%
AWCI
129
Alpine Woods Capital Investors
New York
$14.8M
OMC
130
Old Mission Capital
Illinois
$14.7M +$14.5M +191,698 New
PSUF
131
People's United Financial
Connecticut
$14.5M +$312K +4,128 +2%
Bank of Montreal
132
Bank of Montreal
Ontario, Canada
$14.5M -$43K -569 -0.3%
FGP
133
Foyston, Gordon, & Payne
Ontario, Canada
$14.4M +$6.8M +90,054 +93%
Russell Investments Group
134
Russell Investments Group
United Kingdom
$14.2M +$14M +185,033 New
Janney Montgomery Scott
135
Janney Montgomery Scott
Pennsylvania
$14.1M +$735K +9,732 +6%
HCM
136
Howland Capital Management
Massachusetts
$14.1M +$203K +2,689 +1%
VanEck Associates
137
VanEck Associates
New York
$14.1M -$4.42M -58,531 -24%
HTHT
138
Hemenway Trust Hemenway Trust
New Hampshire
$13.9M +$368K +4,873 +3%
CIM
139
Confluence Investment Management
Missouri
$13.7M +$560K +7,413 +4%
JGUA
140
John G. Ullman & Associates
New York
$13.6M +$3.43M +45,444 +35%
Citigroup
141
Citigroup
New York
$13.5M +$2.83M +37,419 +27%
WAM
142
World Asset Management
Michigan
$13.2M -$34K -450 -0.3%
CIM
143
Corda Investment Management
Texas
$13M +$1.22M +16,112 +11%
CGH
144
Crossmark Global Holdings
Texas
$12.6M +$12.3M +163,260 New
Comerica Bank
145
Comerica Bank
Texas
$12.6M +$162K +2,148 +1%
GGI
146
Godsey & Gibb Inc
Virginia
$12.3M -$623K -8,245 -5%
TD Asset Management
147
TD Asset Management
Ontario, Canada
$12M +$1.58M +20,963 +16%
PHS
148
Pekin Hardy Strauss
Illinois
$11.9M -$152K -2,012 -1%
CBT
149
Capital Bank & Trust
California
$11.9M +$607K +8,036 +5%
BCAM
150
Boston Common Asset Management
Massachusetts
$11.5M +$184K +2,438 +2%

NVS Hedge Fund Activity: Q3 2017 in Review

937 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Novartis (NVS) for Q3 2017, worth a combined $22.2B — up 2.2% from $21.7B a quarter earlier.

Buyers outnumbered sellers: 70 funds opened new NVS positions and 44 closed out — a net gain of 26 holders — while 348 added to existing stakes and 336 trimmed.

The largest buyer was Bank of America, adding an estimated $158M. The largest seller was Dodge & Cox, cutting an estimated $464M.

  • 937 institutional investors held Novartis (NVS) as of Q3 2017, up from 920 in Q2 2017.
  • Funds reported $22.2B of Novartis stock for Q3 2017, up 2.2% quarter-over-quarter.
  • 70 funds opened new Novartis positions in Q3 2017 and 44 closed out, a net change of +26 holders.
  • The largest Novartis buyer in Q3 2017 was Bank of America, an estimated $158M added.
  • The largest Novartis seller in Q3 2017 was Dodge & Cox, an estimated $464M sold.

Based on aggregated 13F filings for Q3 2017.